The dramatic reports of a recent study concluding that delirium leads to lingering cognitive impairments in three out of four patients hospitalized in an intensive care unit are consistent with findings from similar research conducted at UMass Medical School by neuroepidemiologist Jane Saczynski, PhD.
UMass Medical School’s MassBiologics has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent the recurrence of hepatitis C virus in patients receiving a liver transplant.
Jun R. Huh, PhD, assistant professor of medicine in the Division of Infectious Diseases & Immunology, received the 2013 Smith Family Foundation Award for Excellence in Biomedical Research, a highly competitive award intended to help launch the careers of newly independent biomedical researchers.
UMMS RNA expert Melissa J. Moore, PhD, and Harvard Medical School’s Ananth Karumanchi, MD, recently received a $1 million grant from the Bill & Melissa Gates Foundation to develop a novel, RNA-based therapy for preeclampsia.
Autism researcher Teresa Mitchell, PhD, comments on a recent study that found autism spectrum disorder indicators might begin to show up in infants as young as 2 months old.
“Anti-gal” technology developed at UMMS has been licensed to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers.
Job Dekker, PhD, and Noam Kaplan, PhD, have developed a new method for piecing together the short DNA reads produced by next-generation sequencing technologies that are the basis for building complete genome sequences.
UMass Medical School Chief of Police Jack Luippold (left) and Director of Auxiliary Services Bill Tsaknopoulos were honored by Chancellor Michael F. Collins as the inaugural recipients of two new Chancellor’s Awards at the Nov. 20 Employee Service Awards Celebration.